These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31429896)

  • 1. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.
    Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Alexopoulos GS; Rudorfer MV; Marino P; Banerjee S; Pollari CD; Wu Y; Voineskos AN; Mulsant BH;
    JAMA; 2019 Aug; 322(7):622-631. PubMed ID: 31429896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.
    Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Mulsant BH; Rudorfer MV; Marino P;
    BMC Psychiatry; 2013 Jan; 13():38. PubMed ID: 23351522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.
    Voineskos AN; Mulsant BH; Dickie EW; Neufeld NH; Rothschild AJ; Whyte EM; Meyers BS; Alexopoulos GS; Hoptman MJ; Lerch JP; Flint AJ
    JAMA Psychiatry; 2020 Jul; 77(7):674-683. PubMed ID: 32101271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study.
    Flint AJ; Rothschild AJ; Whyte EM; Alexopoulos GS; Mulsant BH; Marino P; Banerjee S; Pollari CD; Wu Y; Voineskos AN; Meyers BS;
    Am J Geriatr Psychiatry; 2021 Jul; 29(7):645-654. PubMed ID: 33268022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).
    Meyers BS; Flint AJ; Rothschild AJ; Mulsant BH; Whyte EM; Peasley-Miklus C; Papademetriou E; Leon AC; Heo M;
    Arch Gen Psychiatry; 2009 Aug; 66(8):838-47. PubMed ID: 19652123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization treatment of remitted psychotic depression: the STOP-PD study.
    Bingham KS; Meyers BS; Mulsant BH; Rothschild AJ; Whyte EM; Banerjee S; Artis AS; Alexopoulos GS; Flint AJ;
    Acta Psychiatr Scand; 2018 Sep; 138(3):267-273. PubMed ID: 29959765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.
    Blumberger DM; Mulsant BH; Emeremni C; Houck P; Andreescu C; Mazumdar S; Whyte E; Rothschild AJ; Flint AJ; Meyers BS
    J Psychiatr Res; 2011 Jul; 45(7):896-901. PubMed ID: 21300377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial.
    Flint AJ; Iaboni A; Mulsant BH; Rothschild AJ; Whyte EM; Meyers BS;
    Am J Geriatr Psychiatry; 2014 Apr; 22(4):332-6. PubMed ID: 23642462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression.
    Bingham KS; Rothschild AJ; Mulsant BH; Whyte EM; Meyers BS; Banerjee S; Szanto K; Flint AJ;
    J Clin Psychiatry; 2017; 78(8):1149-1154. PubMed ID: 28445632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trial.
    Flint AJ; Bingham KS; Alexopoulos GS; Marino P; Mulsant BH; Neufeld NH; Rothschild AJ; Voineskos AN; Whyte EM; Meyers BS;
    J Psychiatr Res; 2023 Jan; 157():285-290. PubMed ID: 36535116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study.
    Men X; Marshe V; Elsheikh SS; Alexopoulos GS; Marino P; Meyers BS; Mulsant BH; Rothschild AJ; Voineskos AN; Whyte EM; Kennedy JL; Flint AJ; Müller DJ
    Neuropsychobiology; 2023; 82(3):168-178. PubMed ID: 37015192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.
    Weissman J; Flint A; Meyers B; Ghosh S; Mulsant B; Rothschild A; Whyte E;
    Psychiatry Res; 2012 May; 197(3):221-6. PubMed ID: 22464991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study.
    Song J; Mulsant BH; Sanches M; Alexopoulos GS; Marino P; Meyers BS; Rothschild AJ; Voineskos AN; Whyte EM; Flint AJ; Gerretsen P;
    J Affect Disord; 2023 Mar; 325():29-34. PubMed ID: 36592671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.
    Østergaard SD; Meyers BS; Flint AJ; Mulsant BH; Whyte EM; Ulbricht CM; Bech P; Rothschild AJ;
    J Affect Disord; 2014 May; 160():68-73. PubMed ID: 24439830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.
    Hedayati SS; Gregg LP; Carmody T; Jain N; Toups M; Rush AJ; Toto RD; Trivedi MH
    JAMA; 2017 Nov; 318(19):1876-1890. PubMed ID: 29101402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression.
    Victoria LW; Whyte EM; Butters MA; Meyers BS; Alexopoulos GS; Mulsant BH; Rothschild AJ; Banerjee S; Flint AJ
    Am J Geriatr Psychiatry; 2017 Jun; 25(6):672-679. PubMed ID: 28285771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features.
    Kim HK; Voineskos AN; Neufeld NH; Alexopoulos GS; Bingham KS; Flint AJ; Marino P; Rothschild AJ; Whyte EM; Mulsant BH
    Mol Psychiatry; 2024 Aug; 29(8):2459-2466. PubMed ID: 38503927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.
    Deligiannidis KM; Rothschild AJ; Barton BA; Kroll-Desrosiers AR; Meyers BS; Flint AJ; Whyte EM; Mulsant BH;
    J Clin Psychiatry; 2013 Oct; 74(10):1003-9. PubMed ID: 24229753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.